Azadirachta Indica Bark

Dosage for Azadirachta Indica Bark is highly individualized and must be determined by an allergist based on the patient's sensitivity level. There is no 'standard' dose for all patients.

Diagnostic Dosing

• Skin Prick Test: Usually one drop of a 1:10 or 1:20 w/v concentration applied to the skin, followed by a puncture or prick through the drop.
• Intradermal Test: If the prick test is negative, a small volume (0.02 to 0.05 mL) of a much more dilute solution (e.g., 1:1000 w/v) may be injected into the dermis.

Immunotherapy Dosing (SCIT)

• Build-up Phase: Treatment typically begins with a very low dose (e.g., 0.05 mL of a 1:100,000 w/v dilution). Doses are increased weekly or bi-weekly by 50% to 100% until the maintenance dose is reached.
• Maintenance Phase: Once the maximum tolerated dose (maintenance dose) is achieved, the interval between injections is increased to every 2 to 4 weeks. A common maintenance volume is 0.5 mL of a 1:100 or 1:20 w/v concentrate, but this varies significantly.

Azadirachta Indica Bark is generally considered safe for use in children, provided the child is old enough to cooperate with the procedure and the benefits outweigh the risks.

• Dosing: Pediatric dosing follows the same weight-to-volume principles as adult dosing, though initial doses may be even more conservative in highly sensitive children.
• Approval: While no specific age cutoff is mandated by the FDA, many clinicians wait until a child is at least 5 years old to begin immunotherapy due to the risk of systemic reactions and the need for the patient to communicate symptoms.

Renal Impairment

No specific dose adjustments are required for patients with renal impairment, as the extract is not primarily cleared by the kidneys. However, the patient's overall health and ability to tolerate a systemic reaction must be considered.

Hepatic Impairment

No dose adjustments are required for hepatic impairment. The metabolic pathway for allergenic proteins does not involve the liver's CYP450 system.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The dose may need to be adjusted or the treatment avoided if the patient is taking beta-blockers, which can complicate the treatment of an allergic reaction.

Azadirachta Indica Bark extracts are for professional use only and must never be self-administered by the patient.

• Administration: Immunotherapy injections are given subcutaneously, usually in the posterior aspect of the upper arm. The site should be rotated between injections.
• Observation: Patients MUST remain in the medical office for at least 30 minutes after any injection to monitor for signs of a systemic allergic reaction (anaphylaxis).
• Storage: Vials should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Potency may be lost if the extract is left at room temperature for extended periods.

Consistency is critical in immunotherapy. If a dose is missed during the build-up phase, the next dose may need to be reduced depending on how much time has elapsed.

• < 1 week late: Continue with the planned increase.
• 1-2 weeks late: Repeat the last dose.
• > 3 weeks late: Significant dose reduction (e.g., 2-3 steps back) is usually required to ensure safety.

An overdose of Azadirachta Indica Bark extract can lead to a severe systemic reaction or anaphylaxis.

• Signs: Hives, swelling of the throat, wheezing, rapid pulse, dizziness, or fainting.
• Emergency Measures: Immediate administration of epinephrine (1:1000) intramuscularly is the primary treatment. Oxygen, intravenous fluids, and antihistamines may also be required. If an overdose occurs at a clinic, the medical staff will follow established emergency protocols.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to adjust your dose or administration schedule without medical guidance.

The most frequent side effects associated with Azadirachta Indica Bark are localized to the site of administration. These are expected immunological responses and usually do not require discontinuation of therapy.

• Local Swelling (Wheal): A raised, itchy bump at the injection or test site. This typically appears within 15 minutes and resolves within a few hours.
• Erythema (Flare): Redness of the skin surrounding the injection site. This is a result of localized vasodilation.
• Pruritus (Itching): Intense itching at the site, which can be managed with cold compresses or topical hydrocortisone if persistent.
• Delayed Local Reaction: Swelling that appears 6 to 24 hours after an injection. This can feel like a firm, warm knot under the skin and may last for 1-2 days.

These reactions are more systemic in nature but are generally not life-threatening if managed promptly.

• Generalized Urticaria (Hives): Itchy welts appearing on parts of the body distant from the injection site.
• Rhinitis: Sneezing, nasal congestion, or a runny nose shortly after administration.
• Conjunctivitis: Red, itchy, or watery eyes.
• Mild Cough: A transient, non-productive cough.

• Angioedema: Significant swelling of the deeper layers of the skin, often around the eyes or lips.
• Laryngeal Edema: Swelling of the throat, which can cause difficulty swallowing or a feeling of 'fullness' in the throat.
• Vasovagal Syncope: Fainting or lightheadedness due to a drop in blood pressure, often triggered by the needle stick rather than the extract itself.

> Warning: Stop the administration process and call for emergency medical help immediately if you experience any of these symptoms after an injection.

• Anaphylaxis: A severe, multi-system allergic reaction. Symptoms include a sudden drop in blood pressure (shock), rapid or weak pulse, narrowing of the airways, and loss of consciousness.
• Severe Bronchospasm: Intense wheezing and difficulty breathing that does not respond to a rescue inhaler.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.
• Cardiac Arrest: In extremely rare cases, severe anaphylaxis can lead to cardiovascular collapse.

There are no known long-term 'toxic' effects of Azadirachta Indica Bark, as it is a biological protein extract. However, prolonged immunotherapy can lead to:

• Persistent Local Granulomas: Small, hard nodules at the injection sites that may take months to resolve.
• Immunological Shift: While the goal is a beneficial shift in the immune system, very rarely, patients may develop new sensitivities to other components in the extract mixture.

While Azadirachta Indica Bark itself may not have a specific individual black box warning, the entire class of Allergenic Extracts carries a general warning regarding the risk of severe systemic reactions.

FDA Class Warning Summary: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients with unstable asthma are at higher risk. Extracts should only be administered in a setting where emergency equipment and trained personnel are immediately available. Patients should be observed for at least 30 minutes following administration.

Report any unusual symptoms to your healthcare provider immediately. Even a large local reaction should be reported, as it may be a precursor to a systemic reaction at the next dose.

Azadirachta Indica Bark extract is a potent biological agent. It must only be used by clinicians who are experts in allergy and immunology. Patients must be fully informed of the risks of immunotherapy, particularly the risk of anaphylaxis. Before starting treatment, a thorough medical history must be taken to identify any conditions that might make a systemic reaction more dangerous.

No specific FDA black box warning exists solely for Azadirachta Indica Bark, but it falls under the mandatory class-wide warnings for all allergenic extracts. These warnings emphasize that:

1. 1Anaphylaxis Risk: Systemic reactions can occur at any time during treatment, even in patients who have previously tolerated the same dose.
2. 2Facility Requirements: Injections must be given in a medical facility equipped with epinephrine, oxygen, and airway management tools.
3. 3Observation Period: A 30-minute mandatory wait time is required after every injection.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Risk factors include high sensitivity levels, rapid dose escalation, and the use of highly concentrated extracts.
• Asthma Status: Patients with uncontrolled or severe asthma are at a significantly higher risk for fatal systemic reactions. Immunotherapy should be withheld if the patient is experiencing an asthma flare or if their FEV1 (Forced Expiratory Volume) is significantly below their baseline.
• Cardiovascular Disease: Patients with pre-existing heart conditions may be less able to survive the physiological stress of anaphylaxis or the side effects of epinephrine.
• Beta-Blocker Use: Patients taking beta-blockers (e.g., metoprolol, propranolol) may be resistant to the effects of epinephrine, making the treatment of anaphylaxis extremely difficult.

• Peak Flow/Spirometry: For asthmatic patients, lung function should be checked before each injection.
• Injection Site Inspection: The healthcare provider must check the site for large local reactions from the previous visit before administering the next dose.
• Symptom Review: Patients should be asked about any delayed reactions or new symptoms since their last visit.

Azadirachta Indica Bark does not typically cause drowsiness. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have fully recovered and been cleared by a physician.

There is no direct interaction between alcohol and Azadirachta Indica Bark. However, alcohol consumption can cause vasodilation, which may theoretically increase the rate of allergen absorption or worsen the symptoms of an allergic reaction. It is generally advised to avoid alcohol for several hours after an immunotherapy injection.

Immunotherapy is typically a 3-to-5-year commitment. Stopping the treatment early may result in the return of allergy symptoms. There is no 'withdrawal syndrome' associated with stopping Azadirachta Indica Bark, but the immunological tolerance will gradually fade if the maintenance phase is not completed.

> Important: Discuss all your medical conditions with your healthcare provider before starting Azadirachta Indica Bark, especially any history of heart problems or breathing difficulties.

While there are few absolute contraindications, the following combinations are generally avoided due to extreme safety risks:

• Beta-Adrenergic Blockers (Non-selective and Selective): Drugs like Propranolol, Atenolol, or Timolol eye drops. These drugs inhibit the action of epinephrine. If a patient on beta-blockers has an anaphylactic reaction to Azadirachta Indica Bark, the standard treatment (epinephrine) may fail to work, leading to a potentially fatal outcome.
• Unstable Asthma Medications: If a patient requires high-dose oral corticosteroids or frequent rescue inhaler use for unstable asthma, the use of allergenic extracts is contraindicated until the asthma is stabilized.

• ACE Inhibitors: Drugs like Lisinopril or Enalapril. There is some evidence that ACE inhibitors may increase the risk of severe systemic reactions to immunotherapy or make reactions more difficult to treat by interfering with the body's natural compensatory mechanisms (the renin-angiotensin system).
• MAO Inhibitors (MAOIs): Drugs like Phenelzine or Selegiline. These can potentiate the effect of epinephrine, leading to a hypertensive crisis if epinephrine is needed to treat a reaction.
• Tricyclic Antidepressants (TCAs): Like Amitriptyline. Similar to MAOIs, these can increase the cardiovascular sensitivity to epinephrine.

• Antihistamines: Drugs like Loratadine, Cetirizine, or Diphenhydramine. While not dangerous, these drugs can mask the early warning signs of a systemic reaction (like itching or hives) and can suppress the results of diagnostic skin testing. Antihistamines should be discontinued 3 to 7 days prior to skin testing.
• Topical Steroids: When applied to the skin testing site, these can suppress the inflammatory response and lead to a false-negative result.

There are no known direct food-drug interactions with Azadirachta Indica Bark. However, patients with a known 'Oral Allergy Syndrome' or cross-reactivity between Neem and certain foods should be monitored. Patients should avoid eating a heavy meal or exercising vigorously immediately before or after an injection, as increased body temperature and circulation can speed up allergen absorption.

• St. John's Wort: May theoretically affect the metabolism of other medications used to treat allergic reactions, though no direct link to Neem extract is established.
• Neem Supplements: Patients taking oral Neem capsules or using Neem oil for traditional medicinal purposes should inform their allergist. High systemic levels of Neem components from supplements could theoretically lower the threshold for a reaction to the allergenic extract.

• Skin Testing: Azadirachta Indica Bark is itself a 'test.' Its results are the primary data point.
• Total IgE and Specific IgE (RAST/ImmunoCAP): Treatment with Azadirachta Indica Bark immunotherapy will eventually lead to changes in these lab values (initially a rise in specific IgE, followed by a long-term decline and a rise in IgG4).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter eye drops and cold medicines.

Azadirachta Indica Bark must NEVER be used in the following circumstances:

1. 1Severe, Unstable, or Uncontrolled Asthma: Patients with a baseline FEV1 <70% of predicted or those with frequent exacerbations are at an unacceptable risk for fatal bronchospasm during a systemic reaction.
2. 2History of Severe Anaphylaxis to Neem: If a patient has previously had a life-threatening reaction to a very small dose of Neem extract, the risks of immunotherapy likely outweigh the benefits.
3. 3Recent Myocardial Infarction or Unstable Angina: The heart cannot tolerate the stress of a systemic reaction or the administration of epinephrine.
4. 4Inability to Communicate: Patients who cannot report early symptoms of a reaction (e.g., very young infants or patients with severe cognitive impairment) should not receive immunotherapy.

These conditions require a careful risk-benefit analysis by the physician:

• Pregnancy: Immunotherapy is generally not started during pregnancy due to the risk of anaphylaxis causing fetal hypoxia. However, if a patient is already on a stable maintenance dose and becomes pregnant, the treatment may be continued.
• Autoimmune Diseases: There is a theoretical concern that stimulating the immune system with extracts could worsen conditions like Lupus or Rheumatoid Arthritis, though clinical data is limited.
• Malignancy: Patients with active cancer may have altered immune responses.

Azadirachta Indica belongs to the Meliaceae family (Mahogany family). Patients who are highly allergic to other members of this family or to certain botanical extracts may show cross-reactivity. Healthcare providers should be aware of the patient's full allergy profile to anticipate unusually strong reactions.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Azadirachta Indica Bark. Ensure you provide a full list of all allergies and past reactions.

Azadirachta Indica Bark is classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm.

• Risks: The primary risk to the fetus is not the extract itself, but the potential for maternal anaphylaxis. A severe drop in maternal blood pressure or respiratory failure can lead to fetal hypoxia (lack of oxygen) and miscarriage or preterm labor.
• Clinical Practice: Allergists typically do not initiate the build-up phase of immunotherapy during pregnancy. If a woman is already at a maintenance dose and is tolerating it well, the dose is usually maintained or slightly reduced, but not increased.

It is not known whether Azadirachta Indica Bark allergenic proteins are excreted in human milk. However, because these are large proteins and the amount administered is very small, it is highly unlikely that they would be absorbed intact by the nursing infant in any significant quantity. The American Academy of Allergy, Asthma & Immunology (AAAAI) generally considers immunotherapy to be compatible with breastfeeding.

Azadirachta Indica Bark is used in children, but with caution.

• Safety: The safety profile is similar to adults, but children may have more difficulty describing the early 'aura' of an allergic reaction (e.g., itchy palms, 'funny' feeling in the throat).
• Efficacy: Immunotherapy is often very effective in children and may prevent the development of new allergies or the progression from allergic rhinitis to asthma (the 'allergic march').

Older adults (over age 65) require special consideration.

• Cardiovascular Risk: Increased prevalence of hypertension and coronary artery disease makes the use of epinephrine riskier.
• Polypharmacy: Older patients are more likely to be on beta-blockers or ACE inhibitors, which complicate the safety of the extract.
• Renal Function: While not a primary clearance route, overall frailty must be assessed.

There are no specific guidelines for Azadirachta Indica Bark in renal impairment. However, clinicians should be cautious if the patient has end-stage renal disease (ESRD), as their physiological reserve to handle a systemic reaction is diminished.

No adjustments are necessary for patients with liver disease. The processing of allergenic proteins by the immune system does not depend on hepatic function.

> Important: Special populations require individualized medical assessment. Always inform your specialist if you are planning to become pregnant or have new health diagnoses.

Azadirachta Indica Bark extract acts as an exogenous antigen. At the molecular level, the extract contains various proteins and glycoproteins that function as allergens.

1. 1Diagnostic Phase: Upon intradermal injection, these proteins bind to specific IgE antibodies on the surface of mast cells. This triggers the activation of the Syk-pathway and the subsequent release of pre-formed mediators (histamine) and newly synthesized mediators (leukotrienes).
2. 2Therapeutic Phase: Repeated exposure via SCIT induces a state of 'anergy' or 'tolerance.' This involves the induction of IL-10-secreting Regulatory T cells (Tregs), which suppress the Th2 response. Furthermore, B cells are stimulated to switch production from IgE to IgG4. IgG4 acts as a 'decoy' or 'blocking' antibody that captures the Neem allergens before they can reach the mast-cell-bound IgE.

• Dose-Response: There is a clear dose-response relationship in skin testing; higher concentrations produce larger wheals. In immunotherapy, higher maintenance doses are generally associated with better long-term efficacy, provided they are tolerated.
• Onset of Effect: Diagnostic reactions occur within 15-20 minutes. The therapeutic effect of immunotherapy is slow, often taking 6 to 12 months to show significant symptom reduction.
• Duration of Effect: A successful course of immunotherapy (3-5 years) can provide symptom relief for many years after discontinuation, a phenomenon known as 'disease modification.'

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Topical) |

| Protein Binding | Primarily to IgE and IgG4 antibodies |

| Half-life | Minutes to hours (Proteins are rapidly degraded) |

| Tmax | 15-30 minutes for local reaction |

| Metabolism | Proteolytic degradation in tissues |

| Excretion | Catabolic amino acid recycling |

• Composition: A complex mixture of proteins, glycoproteins, and polysaccharides extracted from the bark of Azadirachta indica.
• Solubility: Soluble in aqueous buffers and glycerin-water mixtures.
• Molecular Weight: Ranges from 10 kDa to over 70 kDa for the various allergenic protein fractions.

Azadirachta Indica Bark is a Non-Standardized Plant Allergenic Extract. It is grouped with other tree bark and pollen extracts used in clinical allergy practice. Unlike 'Standardized' extracts (like those for Grass or Dust Mites), the potency is not measured in units but is defined by the weight of the raw material used per volume of solvent (w/v).